Aptose Biosciences Company Executives
| APS Stock | CAD 2.22 0.02 0.89% |
Aptose Biosciences employs about 13 people. The company is managed by 8 executives with a total tenure of roughly 12 years, averaging almost 1.0 years of service per executive, having 1.63 employees per reported executive. Analysis of Aptose Biosciences' management performance can provide insight into the firm performance.
| William Rice Chairman Chairman, CEO and Pres |
Aptose |
Aptose Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (1.3546) % which means that it has lost $1.3546 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.9413) %, meaning that it generated substantial loss on money invested by shareholders. Aptose Biosciences' management efficiency ratios could be used to measure how well Aptose Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Aptose Biosciences' Return On Capital Employed is very stable compared to the past year. As of the 21st of July 2025, Return On Equity is likely to grow to 5.88, while Return On Tangible Assets are likely to drop (2.64). At this time, Aptose Biosciences' Other Current Assets are very stable compared to the past year. As of the 21st of July 2025, Fixed Asset Turnover is likely to grow to 0.75, while Total Assets are likely to drop about 9.6 M.As of the 21st of July 2025, Common Stock Shares Outstanding is likely to drop to about 1.9 M. In addition to that, Net Loss is likely to drop to about (39.5 M)
Aptose Biosciences Workforce Comparison
Aptose Biosciences is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 59.0. Aptose Biosciences totals roughly 13.0 in number of employees claiming about 22% of equities under Health Care industry.
Aptose Biosciences Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Aptose Biosciences Price Series Summation is a cross summation of Aptose Biosciences price series and its benchmark/peer.
Aptose Biosciences Notable Stakeholders
An Aptose Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aptose Biosciences often face trade-offs trying to please all of them. Aptose Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aptose Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Rice | Chairman, CEO and Pres | Profile | |
| Fletcher Payne | CFO, VP | Profile | |
| Brooks MBA | VP Controller | Profile | |
| Philippe Ledru | Senior Officer | Profile | |
| Janet CA | VP Fin | Profile | |
| Rafael MD | Senior Officer | Profile | |
| Roger BSc | Vice Operations | Profile | |
| Marc Wiles | Senior Affairs | Profile |
About Aptose Biosciences Management Performance
The success or failure of an entity such as Aptose Biosciences often depends on how effective the management is. Aptose Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aptose management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aptose management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.51) | (2.64) | |
| Return On Capital Employed | 20.67 | 21.70 | |
| Return On Assets | (2.51) | (2.64) | |
| Return On Equity | 5.60 | 5.88 |
Aptose Biosciences Workforce Analysis
Traditionally, organizations such as Aptose Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aptose Biosciences within its industry.Aptose Biosciences Manpower Efficiency
Return on Aptose Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2M | |
| Net Loss Per Executive | 3.2M | |
| Working Capital Per Employee | 390.1K | |
| Working Capital Per Executive | 633.9K |
Other Information on Investing in Aptose Stock
Aptose Biosciences financial ratios help investors to determine whether Aptose Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aptose with respect to the benefits of owning Aptose Biosciences security.